Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.

Lene Kongsgaard NielsenFredrik SchjesvoldSören MöllerNina GuldbrandsenMarkus HanssonKari RemesValdas PeceliunasNiels AbildgaardHenrik GregersenMadeleine T King

Published in: Journal of patient-reported outcomes (2024)

Kd maintenance therapy after salvage ASCT did not adversely affect overall HRQL, but adjustment for HRQL reduced the PFS compared to unadjusted PFS. PFS of maintenance therapy should be quality-adjusted to balance the benefits and HRQL impact.

Keyphrases

multiple myeloma
stem cell transplantation
free survival
high dose
low dose
bone marrow
quality improvement
stem cells
newly diagnosed